Oncorena
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Medicon Village Scheeletorget 1, Lund, S...Phone Number
+46 706649477Website
www.oncorena.seRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Oncorena
Oncorena AB is a Swedish privately-held limited pharma company headquarted in Lund. The company develops a completely new and potentially revolutionizing treatment for patients with metastatic kidney cancer. The treatment is based on research at the University of Gothenburg, Sweden, led by professors Börje Haraldsson and Jenny Nyström.Explore more
Popular SearchesOncorenaOncorena ABOncorena AB - Oncorena ABOncorena Holding ABSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncorena your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Oncorena launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Oncorena recently announced quarterly report
Check out if Oncorena is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Oncorena
Check if Oncorena has recently received funding, and reach out quickly before it becomes old news!
Oncorena, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Oncorena has new funding data
Click to see if Oncorena had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Oncorena as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Oncorena is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncorena is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncorena.
Oncorena Tech Stack
A closer look at the technologies used by Oncorena
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Promotion
Executive Move
Börje Haraldsson, Chief Scientific Officer, has assumed the role of Chief Executive Officer.
Funding
Oncorena News & Media
Oncorena receives FDA approval to initiate studies in the US
LUND, Sweden, March 18, 2025 /PRNewswire/ -- Oncorena is pleased to announce that the FDA has approved the Company's IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm study on safety, tolerability and anti-tumor efficacy of orellanine...Oncorena receives FDA approval to initiate studies in the US
LUND, Sweden, March 18, 2025 /PRNewswire/ -- Oncorena is pleased to announce that the FDA has approved the Company's IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm study on safety, tolerability and anti-tumor efficacy of orellanine...Oncorena’s First Patient Treated with ONC175 (orellanine) in clinial phase I/II trial in Patients with Metastatic Renal Cancer and Dialysis at Karolinska University Hospital in Stockholm, Sweden
LUND, SWEDEN, September 4, 2023 – Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis. The first treatment was conducted on August 8 without any complication at the Center for Clincal Cancer studies at Karolinska University Hospital, Stockholm, Sweden. The study examines safety, tolerability, pharmacokinetics and antitumor effect when treated with ONC175. ”I am happy to announcBörje Haraldsson appointed CEO of Oncorena AB
LUND, Sweden, June 20, 2022 /PRNewswire/ -- Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer, announces that the Board of Directors of Oncorena AB has appointed Professor Börje Haraldsson as CEO of the company,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncorena
Sign Up For FreeTo access detailed company insights
Oncorena AB is a Swedish privately-held limited pharma company headquarted in Lund. The company develops a completely new and potentially revolutionizing treatment for patients with metastatic kidney cancer. The treatment is based on research at the University of Gothenburg, Sweden, led by professors Börje Haraldsson and Jenny Nyström.... Read More
